LONGEVITY & CELLULAR HEALTH / MATRIX
Three Compounds, Side by Side
Where Epitalon, MOTS-c, and NAD+ converge on the biology of aging — and how far the evidence behind each one actually reaches.
The short version
This page lines up Epitalon, MOTS-c, and NAD+ on the dimensions that matter when reading longevity research: compound class, the specific aging axis each targets, where it has been studied, how strong that evidence is, regulatory standing, and the single most important caution for each. The headline finding is this: all three are studied in the context of cellular aging and healthspan, but they are at very different stages of evidence. NAD+ and its precursors have human RCTs, real blood-level data, and a clear biological mechanism — but hard clinical anti-aging endpoints remain unproven. Epitalon has decades of preclinical and observational human data from a single Russian research lineage, with limited but growing independent replication. MOTS-c has strong animal mechanistic data and one human observational biomarker association, with no human intervention trials. None is an approved medicine for aging or any other indication.
The comparison matrix
| Dimension | Epitalon | MOTS-c | NAD+ |
|---|---|---|---|
| Compound class | Synthetic AEDG tetrapeptide (4 aa) | Mitochondrial-encoded MDP (16 aa) | Endogenous redox coenzyme / dietary supplement |
| Primary aging axis | Telomere shortening; pineal neuroendocrine decline | Mitochondrial stress signaling; metabolic aging | NAD+ coenzyme depletion; sirtuin/PARP substrate deficit |
| Best evidence (model) | Human cell lines (telomerase) [2][4]; mouse lifespan [6]; human observational cohort [5] | Mouse performance across age groups [11]; human biomarker association (n=94) [9] | Human RCTs of NMN/NR raising blood NAD+ [14][17]; human insulin sensitivity [15] |
| Evidence maturity | Preclinical + observational human; largely single-lineage; limited independent replication [1] | Preclinical only (animal + cell); no human intervention trials [10] | RCT-level for biomarker; pre-RCT for hard aging endpoints [13] |
| Regulatory status | Not approved anywhere; research chemical (US, EU, UK) | Not approved; research-chemical only | Dietary supplement (NMN/NR); NMN supplement status contested by FDA |
| WADA status | Not specifically listed (verify periodically) | Prohibited in elite sport (metabolic-modulator category) | Not prohibited |
| Key caution | Evidence concentrated in one research lineage; human data observational, not randomized [1][5] | No human intervention data; rodent doses unextrapolatable [10] | Hard anti-aging endpoints unproven in humans; compounded IV form has had endotoxin recall [13] |
Compound class and origin
The three compounds share a theme but differ radically in what they are. Epitalon is a synthetic tetrapeptide, four amino acids long, derived from the amino-acid sequence identified in a bovine pineal extract [1]. MOTS-c is a 16-amino-acid peptide, but unlike Epitalon it is encoded in the mitochondrial genome — a rare peptide class called mitochondrial-derived peptides, which also includes humanin and the SHLPs [10]. NAD+ is not a peptide at all; it is a small-molecule dinucleotide coenzyme that every living cell makes and consumes continuously [16]. Grouping them together is justified by a shared biological context — geroprotection and aging — not by molecular class.
Primary aging axis
Each compound maps to a different part of the aging-biology landscape. Epitalon targets two axes: telomere shortening (by activating telomerase via hTERT upregulation) and the neuroendocrine circadian axis (by stimulating AANAT and raising melatonin in the pineal gland) [2][3][4]. MOTS-c addresses the mitochondrial metabolic stress axis — it is the mitochondrion's own stress signal, activating AMPK and nuclear antioxidant programs when mitochondrial function is challenged [10][12]. NAD+ addresses the coenzyme substrate depletion axis: age-related NAD+ decline starves sirtuins and PARPs of the substrate they need for DNA repair and gene regulation, and the research asks whether replenishing NAD+ restores those functions [16].
Evidence base by model
This is where the three genuinely separate. NAD+ precursors (NMN and NR) have the most robust human evidence: multiple RCTs demonstrate dose-dependent blood NAD+ elevation, with one trial documenting improved walking distance in middle-aged adults [14] and another showing improved muscle insulin sensitivity in prediabetic postmenopausal women [15]. Hard aging endpoints (longevity, disease reduction) remain unproven [13].
Epitalon has a long preclinical record — mouse lifespan extension [6], oocyte protection [7], telomerase activation in human cell lines [4][2] — plus a notable human cohort association (n=266, 6-8 year follow-up) [5]. That human result carries the specific caveat that it lacked randomization and placebo control, so causality cannot be established [5]. A 2025 UK independent telomerase replication [2] is the most meaningful recent corroboration of the core cellular claim.
MOTS-c has strong mechanistic animal data — direct CK2 binding demonstrated in cell-free systems [8], exercise mimicry across mouse age groups [11], retrograde nuclear signaling characterized in human and mouse cells [12] — and one human observational biomarker association in a renal cohort [9]. No human intervention trials exist.
Regulatory and WADA status
None of the three is an FDA- or EMA-approved medicine for aging or any related indication. Epitalon is a research chemical in the US, EU, and UK — not approved anywhere for human use [1]. MOTS-c is similarly research-only, and additionally falls under WADA's prohibited substance categories for elite athletes as a peptide hormone and metabolic modulator. NAD+ occupies unique territory: it and its precursors NMN and NR are sold as dietary supplements and are widely consumed, but NMN's supplement status has been challenged by the FDA on the grounds that it was investigated as a drug, creating regulatory uncertainty. IV-infused NAD+, used in wellness therapy, is a compounded product that is not FDA-approved and has been subject to a Class I safety recall for endotoxin contamination.
Key caution for each
Each compound carries a defining caveat. For Epitalon, it is the evidence concentration: the foundational human observational data and most mechanistic work come from a single Russian research lineage, and the human cohort lacked randomization and placebo control — so the evidence, while real, rests on a narrow methodological base [1][5]. For MOTS-c, it is the complete absence of human interventional data: every claim about exogenous MOTS-c improving aging, metabolism, or performance in humans is extrapolated from animals, with rodent doses that cannot be translated [10]. For NAD+, it is the gap between what is proven (blood NAD+ rises with precursor supplementation) and what is claimed (anti-aging effects in humans) — a gap that a 2025 authoritative review explicitly called out, recommending more rigorous human trials before extrapolating rodent findings [13].
The shared lesson across all three is familiar to anyone who reads this field carefully: mechanistic coherence is not the same as clinical proof, and promising animal data have repeatedly failed to translate to humans in biogerontology. This desk exists to hold that line.